Overview

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Combination With Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy and safety of HLX43 (Anti-PD-L1 ADC) in Combination with Serplulimab (Anti-PD-1 Recombinant Humanized Monoclonal Antibody) as Neoadjuvant Therapy in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Henlius Biotech